


# Current metastatic colorectal cancer treatment guidelines for patients

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 33 of America's leading cancer centers, dedicated to improving patient care, research, and education. NCCN creates clinical guidelines for doctors to follow when treating different types of cancers, including metastatic colorectal cancer (mCRC).

The NCCN Foundation® develops patient guidelines to provide state-of-the-art cancer treatment information in easy-to-understand language for people with cancer and the general public. The NCCN Guidelines for Patients® includes expert information presented in plain language with visuals, charts, and definitions to empower people with cancer and caregivers to talk with their clinicians about the best treatment options. You can find the NCCN Guidelines for Patients under the Patient Resources section at: [nccn.org/patientresources/patient-resources](https://www.nccn.org/patientresources/patient-resources)

These guidelines may give more than one treatment path. You and your doctor will choose the best treatment path for you from the available options, based on your diagnosis and any discussions you may have had about your treatment.<sup>1</sup>

## Two example treatment paths in mCRC\*:



### What is “targeted therapy”?

Targeted therapy uses drugs or other substances to identify and attack specific types of cancer cells. A targeted therapy can be used by itself or with other treatments, like traditional chemotherapy, surgery, or radiation.

\*Other treatment paths are included in the guidelines. Your doctor may recommend a different treatment path.

<sup>†</sup>Depending on the chemotherapy-based treatment regimen being used, a targeted therapy (either bevacizumab, cetuximab, or panitumumab) may be added.

<sup>‡</sup>Your doctor will decide which treatment to use based on certain factors, like your previous treatments, how you responded to them, or whether the tumor has any biomarkers.


**Reference: 1.** Referenced with permission from the National Comprehensive Cancer Network® (NCCN®). © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 4, 2024. To view the most recent and complete version of the recommendations, go online to [NCCN.org](https://www.nccn.org). NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Adapted with permission from the NCCN Guidelines for Patients® for Colon Cancer, 2024. © 2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines for Patients and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines for Patients, go online to [NCCN.org/patientguidelines](https://www.nccn.org/patientguidelines). The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

Adapted with permission from the NCCN Guidelines for Patients® for Rectal Cancer, 2024 © 2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines for Patients and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines for Patients, go online to [NCCN.org/patientguidelines](https://www.nccn.org/patientguidelines). The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.



ONCOLOGY

TAKEDA and  are registered trademarks of Takeda Pharmaceutical Company Limited.  
© 2024 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. US-FRZ-0349 12/2024